Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma
Over the past decade, an “immunotherapy tsunami”, more specifically that involving immune checkpoint inhibitors (ICIs), has overtaken the oncological field. The interaction and cross-talk among tumor cells and several immune cells in the tumor microenvironment are dynamic and complex processes. As i...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/11/3153 |
id |
doaj-91a1cc5df25540e2b61c45a6ba9607fc |
---|---|
record_format |
Article |
spelling |
doaj-91a1cc5df25540e2b61c45a6ba9607fc2020-11-25T03:04:43ZengMDPI AGCancers2072-66942020-10-01123153315310.3390/cancers12113153Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal SarcomaMakito Miyake0Shunta Hori1Takuya Owari2Yuki Oda3Yoshihiro Tatsumi4Yasushi Nakai5Tomomi Fujii6Kiyohide Fujimoto7Department of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanDepartment of Diagnostic Pathology, Nara Medical University, Nara 634-8522, JapanDepartment of Urology, Nara Medical University, Nara 634-8522, JapanOver the past decade, an “immunotherapy tsunami”, more specifically that involving immune checkpoint inhibitors (ICIs), has overtaken the oncological field. The interaction and cross-talk among tumor cells and several immune cells in the tumor microenvironment are dynamic and complex processes. As immune contexture can vary widely across different types of primary tumors and tumor microenvironments, there is still a significant lack of clinically available definitive biomarkers to predict patient response to ICIs, especially in urogenital malignancies. An increasing body of evidence evaluating urological malignancies has proven that tumor-infiltrating lymphocytes (TILs) are a double-edged sword in cancer. There is an urgent need to shed light on the functional heterogeneity in the tumor-infiltrating immune system and to explore its prognostic impact following surgery and other treatments. Notably, we emphasized the difference in the immunological profile among urothelial carcinomas arising from different primary origins, the bladder, renal pelvis, and ureter. Significant differences in the density of FOXP3-positive TILs, CD204-positive tumor-infiltrating macrophages, PD-L1-positive cells, and colony-stimulating factors were observed. This review discusses two topics: (i) the prognostic impact of TILs and (ii) predictive biomarkers for ICIs, to shed light on lymphocyte migration in four solid tumors, the urothelial carcinoma, renal cell carcinoma, prostate cancer, and retroperitoneal sarcoma.https://www.mdpi.com/2072-6694/12/11/3153tumor-infiltrating lymphocyteimmune cellstumor microenvironmentprognosisimmune checkpoint inhibitortreatment response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Makito Miyake Shunta Hori Takuya Owari Yuki Oda Yoshihiro Tatsumi Yasushi Nakai Tomomi Fujii Kiyohide Fujimoto |
spellingShingle |
Makito Miyake Shunta Hori Takuya Owari Yuki Oda Yoshihiro Tatsumi Yasushi Nakai Tomomi Fujii Kiyohide Fujimoto Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma Cancers tumor-infiltrating lymphocyte immune cells tumor microenvironment prognosis immune checkpoint inhibitor treatment response |
author_facet |
Makito Miyake Shunta Hori Takuya Owari Yuki Oda Yoshihiro Tatsumi Yasushi Nakai Tomomi Fujii Kiyohide Fujimoto |
author_sort |
Makito Miyake |
title |
Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma |
title_short |
Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma |
title_full |
Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma |
title_fullStr |
Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma |
title_full_unstemmed |
Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma |
title_sort |
clinical impact of tumor-infiltrating lymphocytes and pd-l1-positive cells as prognostic and predictive biomarkers in urological malignancies and retroperitoneal sarcoma |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-10-01 |
description |
Over the past decade, an “immunotherapy tsunami”, more specifically that involving immune checkpoint inhibitors (ICIs), has overtaken the oncological field. The interaction and cross-talk among tumor cells and several immune cells in the tumor microenvironment are dynamic and complex processes. As immune contexture can vary widely across different types of primary tumors and tumor microenvironments, there is still a significant lack of clinically available definitive biomarkers to predict patient response to ICIs, especially in urogenital malignancies. An increasing body of evidence evaluating urological malignancies has proven that tumor-infiltrating lymphocytes (TILs) are a double-edged sword in cancer. There is an urgent need to shed light on the functional heterogeneity in the tumor-infiltrating immune system and to explore its prognostic impact following surgery and other treatments. Notably, we emphasized the difference in the immunological profile among urothelial carcinomas arising from different primary origins, the bladder, renal pelvis, and ureter. Significant differences in the density of FOXP3-positive TILs, CD204-positive tumor-infiltrating macrophages, PD-L1-positive cells, and colony-stimulating factors were observed. This review discusses two topics: (i) the prognostic impact of TILs and (ii) predictive biomarkers for ICIs, to shed light on lymphocyte migration in four solid tumors, the urothelial carcinoma, renal cell carcinoma, prostate cancer, and retroperitoneal sarcoma. |
topic |
tumor-infiltrating lymphocyte immune cells tumor microenvironment prognosis immune checkpoint inhibitor treatment response |
url |
https://www.mdpi.com/2072-6694/12/11/3153 |
work_keys_str_mv |
AT makitomiyake clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT shuntahori clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT takuyaowari clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT yukioda clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT yoshihirotatsumi clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT yasushinakai clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT tomomifujii clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma AT kiyohidefujimoto clinicalimpactoftumorinfiltratinglymphocytesandpdl1positivecellsasprognosticandpredictivebiomarkersinurologicalmalignanciesandretroperitonealsarcoma |
_version_ |
1724680084524105728 |